Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Issa F. Khouri(The University of Texas MD Anderson Cancer Center), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), James Gajewski(The University of Texas MD Anderson Cancer Center), Cindy Ippoliti(The University of Texas Health Science Center at Houston), S O'Brien(The University of Texas Health Science Center at Houston), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Donna Przepiorka(The University of Texas MD Anderson Cancer Center), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Paolo Anderlini(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Michèle L. Donato(The University of Texas Health Science Center at Houston), A Gee(The University of Texas Health Science Center at Houston), B von Wolff(The University of Texas Health Science Center at Houston), David F. Claxton(The University of Texas MD Anderson Cancer Center), M Körbling(The University of Texas Health Science Center at Houston), Börje S. Andersson(The University of Texas MD Anderson Cancer Center)
Cited by 927
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k